Abstract
There is growing interest in whether adult vaccines such as shingles vaccine may slow biological aging beyond preventing acute infections. Using data from the nationally representative U.S. Health and Retirement Study, we examined whether shingles vaccination is associated with more favorable profiles across seven biological aging domains: inflammation, innate and adaptive immunity, cardiovascular hemodynamics, neurodegeneration, and epigenetic and transcriptomic aging, as well as a composite biological aging score. Analyses included adults aged 70+ in 2016 (n = 3,884), with biological measures drawn from venous blood, flow cytometry, and physical assessments. Weighted linear regressions adjusted for sociodemographic, and health covariates. Shingles vaccination was significantly associated with lower inflammation scores (b=–0.14, p = 0.0027), slower epigenetic (b=–0.17, p = 0.0001) and transcriptomic aging (b=–0.19, p < .0001), and a lower composite biological aging score (b=–0.18, p = 0.0002), suggesting potential benefits for systemic inflammation, molecular and overall biological aging. In contrast, vaccination was linked to higher adaptive immunity scores (b = 0.09, p = 0.0133), an unexpected finding warranting further investigation. Timing analyses indicated that epigenetic, transcriptomic and overall composite biological aging improvements were most pronounced within three years post-vaccination, with slower aging persisting beyond this window. The results support the hypothesis that shingles vaccination may influence key biological systems relevant to aging, though effects appear domain-specific and vary over time. Longitudinal studies are needed to confirm these patterns and explore implications for long-term health. This study adds to emerging evidence that vaccines could play a role in strategies to promote healthy aging by modulating biological systems beyond infection prevention.
I've got my second one next week, I'm passed the 2-6 month period but apparently that's ok. I've also read that generally the second dose is worse than the first one.Oh no, you've just reminded me I'm going to have to have a second one..........the first one was bloody awful.
The second dose typically produces the peak reactogenicity for the series.
- Dose 2: Higher frequency and intensity of pain, redness, fatigue, muscle aches, headache, fever, and chills
healthorskin.com
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions—A Retrospective Cohort Study in the United States
Abstract
Background
Older (≥50 years of age [YoA]) and immunocompromised adults are at higher risk of herpes zoster (HZ). Those with comorbidities are also at increased risk, however, recent US evidence is lacking, especially among 18–49 YoA.
Methods
This US retrospective cohort study (2015–2022, Merative MarketScan Commercial and Medicare Supplemental) compared HZ incidence rates (IRs) in younger immunocompetent adults (18–49 YoA) with comorbidities (asthma, chronic kidney disease [CKD], chronic obstructive pulmonary disease [COPD], depression, diabetes, stress, and trauma) versus immunocompetent adults 50–59 YoA without comorbidities. Adjusted HZ IR ratios (aIRRs) versus 50–59 YoA adults were compared using a predetermined 0.62 non-inferiority margin for the aIRR 95% confidence interval lower limit (95% CI LL). aIRRs were classified as comparable (aIRR 95% CI LL > 0.62 and ≤1.0), significantly higher (aIRR 95% CI LL > 1.0), or inconclusive (any other result). HZ case: diagnostic code B02.2x plus oral antiviral ±7 days. Sensitivity analyses investigated HZ IRs by number of comorbid conditions (1, 2, or ≥3).
Results
HZ IRs were significantly higher (aIRR 95% CI LL > 1.0) from 30 to 39 YoA (aIRR; 95% CI) in asthma (1.19; 1.10–1.29), COPD (1.31; 1.22–1.40), depression (1.31; 1.22–1.40), diabetes (1.18; 1.06–1.32), stress (1.28; 1.11–1.47), and trauma (1.25; 1.17–1.34) populations than immunocompetent 50–59 YoA and from 50 to 59 YoA in CKD (1.50; 1.28–1.77). In sensitivity analyses, HZ IR appeared to increase with more comorbid conditions and age.
Conclusions
The study found that younger adults (30+ YoA) with certain comorbidities have a higher HZ risk than immunocompetent 50–59 YoA adults.
Yes, been there and suffered that !.This is from New England Journal of Medicine's Journal Watch.
https://blogs.jwatch.org/hiv-id-obs...he-shingles-vaccine-answered-here/2019/10/14/
October 14th, 2019
Common Questions About the Shingles Vaccine — Answered Here!
Here’s an interesting email from my friend and ID-colleague Dr. Carlos Del Rio (shared with his permission):
Went Tuesday to see my PCP for a routine visit and had my second dose of Shingrix that day. I had gotten my first dose about 3 months ago and had severe chills and even a fever of 38.5 after the first dose. With the second dose the response was not as severe but did have chills and rigors for about 18 hrs. Stupid of me, but the next day I went to get my labs checked, and everything was fine except my HS-CRP which was 14.72 (nl < 10 and in the past I had been < 1.0).
Anyway…..Shingrix is a good vaccine but it is a tough one to take and really gives you a nice TNF storm!
The rest is at the link.
Im so sorry for you Mij… hopefully by now its not so miserable.I highly recommend everyone getting the Shingrix which I will do when I'm able because it can come back in a different area.
The second half of the 2 dose Shingrix , done severalYes, been there and suffered that !.
Worse than a flue hit for me. Very sore body aches too (weird- wasnt expecting).